InMed Pharmaceuticals INM is a global leader in researching, developing, manufacturing and commercializing rare cannabinoids and cannabinoid analogs. The company is focused on the therapeutic benefits of cannabinol (CBN) as a pipeline of cannabinoid-based drug candidates for the treatment of diseases with high unmet medical needs.
InMed is a clinical-stage company with expertise in the development of biosynthesis, IP, manufacturing and GMP scale-up methodologies. In addition to their innovative research in CBN, InMed Pharmaceuticals is also widely known for its Foundations™ technology – a pediatric, patient-friendly cannabinoid delivery system.
Interested in learning more about the Benzinga Cannabis Capital Conference? Get more information here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!